These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings
Portfolio Pulse from Avi Kapoor
Abbott Laboratories reported better-than-expected Q3 earnings, with sales of $10.64 billion and adjusted EPS of $1.21. Analysts have increased their price targets, with Morgan Stanley raising it to $117 and Piper Sandler to $133. Abbott's shares rose 1.5% following the announcement.
October 17, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott Laboratories reported strong Q3 earnings, surpassing expectations with $10.64 billion in sales and $1.21 EPS. Analysts have raised their price targets, indicating positive sentiment. The stock rose 1.5% post-announcement.
Abbott's better-than-expected earnings and raised price targets by analysts suggest a positive outlook for the stock. The 1.5% increase in stock price post-announcement reflects investor confidence. The company's strong performance and guidance for 2024 further support a positive short-term impact.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100